Please login to the form below

Not currently logged in
Email:
Password:

Tobi Podhaler

This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics